Statement: both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have. sputum cytology is an examination of cells obtained from a sample of sputum.
Primary_evidence: INTERVENTION 1:    Nivolumab + Daratumumab (TNBC)   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) INTERVENTION 2:    Nivolumab + Daratumumab (NSCLC)   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)